OneDigital Investment Advisors LLC Has $476,000 Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

OneDigital Investment Advisors LLC lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 17.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,128 shares of the company’s stock after selling 893 shares during the period. OneDigital Investment Advisors LLC’s holdings in Neurocrine Biosciences were worth $476,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Plato Investment Management Ltd increased its holdings in shares of Neurocrine Biosciences by 2,481.9% in the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after purchasing an additional 10,548 shares during the last quarter. Redwood Investment Management LLC bought a new stake in shares of Neurocrine Biosciences during the 1st quarter valued at approximately $642,000. Shell Asset Management Co. lifted its stake in Neurocrine Biosciences by 132.8% in the 1st quarter. Shell Asset Management Co. now owns 6,828 shares of the company’s stock valued at $942,000 after purchasing an additional 3,895 shares during the last quarter. Tidal Investments LLC increased its holdings in Neurocrine Biosciences by 57.8% in the 1st quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock worth $1,316,000 after purchasing an additional 3,497 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $5,848,000. 92.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Oppenheimer upped their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Guggenheim boosted their price target on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Jefferies Financial Group raised their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $123.29 on Thursday. Neurocrine Biosciences, Inc. has a fifty-two week low of $108.63 and a fifty-two week high of $157.98. The company has a market cap of $12.48 billion, a PE ratio of 33.05 and a beta of 0.35. The business has a 50-day simple moving average of $118.44 and a two-hundred day simple moving average of $132.24.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.